iBio Inc. Quarterly report pursuant to Section 13 or 15(d)

Segment Reporting (Tables)

6 Months Ended

Dec. 31, 2021


	Biopharmaceuticals		Bioprocessing
Three Months Ended December 31, 2021 (in thousands)	iBio, Inc.		iBio CDMO		Eliminations		Total

Revenues - external customers	$	—	$	168	$	—	$	168
Revenues - intersegment		94		430		(524)		—
Cost of goods sold		—		113		—		113
Gross profit		94		485		(524)		55
Research and development		2,213		1,549		(431)		3,331
General and administrative		4,832		3,623		(93)		8,362
Operating loss		(6,950)		(4,688)		—		(11,638)
Interest expense		—		(328)		—		(328)
Interest and other income		41		5		—		46
Consolidated net loss		(6,909)		(5,011)		—		(11,920)
Total assets		172,004		37,633		(83,189)		126,448
Finance lease ROU assets		—		109		—		109
Operating lease ROU assets		3,334		1,957		—		5,291
Fixed assets, net		600		32,281		—		32,881
Intangible assets, net		5,041		—		—		5,041
Amortization of ROU assets		—		147		—		147
Depreciation expense		—		517		—		517
Amortization of intangible assets		123		—		—		123


	Biopharmaceuticals		Bioprocessing
Three Months Ended December 31, 2020 (in thousands)	iBio, Inc.		iBio CDMO		Eliminations		Total

Revenues - external customers	$	190	$	515	$	—	$	705
Revenues - intersegment		238		288		(526)		—
Cost of goods sold		215		(4)		—		211
Gross profit		213		807		(526)		494
Research and development		373		2,302		(301)		2,374
General and administrative		2,971		2,919		(225)		5,665
Operating loss		(3,131)		(4,414)		—		(7,545)
Interest expense		—		(615)		—		(615)
Interest and other income		29		—		—		29
Consolidated net loss		(3,102)		(5,029)		—		(8,131)
Total assets		163,991		33,789		(52,374)		145,406
Finance lease ROU assets		—		26,786		—		26,786
Fixed assets, net		—		5,010		—		5,010
Intangible assets, net		1,185		—		—		1,185
Amortization of ROU assets		—		415		—		415
Depreciation expense		—		114		—		114
Amortization of intangible assets		73		—		—		73


	Biopharmaceuticals		Bioprocessing
Six Months Ended December 31, 2021 (in thousands)	(iBio, Inc.)		(iBio CDMO)		Eliminations		Total

Revenues - external customers	$	84	$	295	$	—	$	379
Revenues - intersegment		176		885		(1,061)		—
Cost of goods sold		—		153		—		153
Gross profit		260		1,027		(1,061)		226
Research and development		3,734		3,016		(908)		5,842
General and administrative		8,316		6,833		(153)		14,996
Operating loss		(11,789)		(8,823)		—		(20,612)
Interest expense		—		(937)		—		(937)
Forgiveness of note payable and accrued interest		—		607		—		607
Interest and other income		77		5		—		82
Consolidated net loss		(11,712)		(9,148)		—		(20,860)
Total assets		172,004		37,633		(83,189)		126,448
Finance lease ROU assets		—		109		—		109
Operating lease ROU assets		3,334		1,957		—		5,291
Fixed assets, net		600		32,281		—		32,881
Intangible assets, net		5,041		—		—		5,041
Amortization of ROU assets		—		563		—		563
Depreciation expense		—		823		—		823
Amortization of intangible assets		211		—		—		211


	Biopharmaceuticals		Bioprocessing
Six Months Ended December 31, 2020 (in thousands)	(iBio, Inc.)		(iBio CDMO)		Eliminations		Total

Revenues - external customers	$	397	$	718	$	—	$	1,115
Revenues - intersegment		476		498		(974)		—
Cost of goods sold		269		49		—		318
Gross profit		604		1,167		(974)		797
Research and development		608		4,147		(519)		4,236
General and administrative		5,643		5,842		(455)		11,030
Operating loss		(5,647)		(8,822)		—		(14,469)
Interest expense		—		(1,229)		—		(1,229)
Interest and other income		32		1		—		33
Consolidated net loss		(5,615)		(10,050)		—		(15,665)
Total assets		163,991		33,789		(52,374)		145,406
Finance lease ROU assets		—		26,786		—		26,786
Fixed assets, net		—		5,010		—		5,010
Intangible assets, net		1,185		—		—		1,185
Amortization of ROU assets		—		830		—		830
Depreciation expense		—		211		—		211
Amortization of intangible assets		145		—		—		145